1. Home
  2. RELI vs ENSC Comparison

RELI vs ENSC Comparison

Compare RELI & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RELI
  • ENSC
  • Stock Information
  • Founded
  • RELI 2013
  • ENSC 2003
  • Country
  • RELI United States
  • ENSC United States
  • Employees
  • RELI N/A
  • ENSC N/A
  • Industry
  • RELI Specialty Insurers
  • ENSC Biotechnology: Pharmaceutical Preparations
  • Sector
  • RELI Finance
  • ENSC Health Care
  • Exchange
  • RELI Nasdaq
  • ENSC Nasdaq
  • Market Cap
  • RELI 3.0M
  • ENSC 3.4M
  • IPO Year
  • RELI N/A
  • ENSC N/A
  • Fundamental
  • Price
  • RELI $1.22
  • ENSC $2.34
  • Analyst Decision
  • RELI
  • ENSC
  • Analyst Count
  • RELI 0
  • ENSC 0
  • Target Price
  • RELI N/A
  • ENSC N/A
  • AVG Volume (30 Days)
  • RELI 54.9K
  • ENSC 5.0M
  • Earning Date
  • RELI 05-14-2025
  • ENSC 05-13-2025
  • Dividend Yield
  • RELI N/A
  • ENSC N/A
  • EPS Growth
  • RELI N/A
  • ENSC N/A
  • EPS
  • RELI N/A
  • ENSC N/A
  • Revenue
  • RELI $14,208,143.00
  • ENSC $6,224,081.00
  • Revenue This Year
  • RELI N/A
  • ENSC N/A
  • Revenue Next Year
  • RELI N/A
  • ENSC N/A
  • P/E Ratio
  • RELI N/A
  • ENSC N/A
  • Revenue Growth
  • RELI 2.40
  • ENSC 256.35
  • 52 Week Low
  • RELI $0.97
  • ENSC $1.62
  • 52 Week High
  • RELI $18.53
  • ENSC $14.67
  • Technical
  • Relative Strength Index (RSI)
  • RELI 55.58
  • ENSC 46.40
  • Support Level
  • RELI $1.01
  • ENSC $1.99
  • Resistance Level
  • RELI $1.33
  • ENSC $2.40
  • Average True Range (ATR)
  • RELI 0.09
  • ENSC 0.26
  • MACD
  • RELI 0.02
  • ENSC 0.02
  • Stochastic Oscillator
  • RELI 65.63
  • ENSC 28.00

About RELI Reliance Global Group Inc.

Reliance Global Group Inc operates as a holding company with diversified interests in the insurance market, as well as other related sectors. The company focuses on growing by pursuing acquisition strategies, initially and focused on wholesale and retail insurance agencies. Its primary strategies is to identify specific risks to reward arbitrage opportunities and develop these on a national platform, thereby increasing revenues and returns, and then identify and acquire undervalued wholesale and retail insurance agencies with operations in growing or underserved segments, expand and optimize their operations, and achieve asset value appreciation while generating interim cash flows. The company generates revenue in the form of commissions.

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: